United States securities and exchange commission logo





                             May 4, 2020

       Jeffrey Nau, Ph.D., M.M.S.
       President and Chief Executive Officer
       Oyster Point Pharma, Inc.
       202 Carnegie Center, Suite 109
       Princeton, New Jersey 08540

                                                        Re: Oyster Point
Pharma, Inc.
                                                            Draft Registration
Statement on Form S-1
                                                            Filed April 27,
2020
                                                            CIK No. 0001720725

       Dear Dr. Nau:

                                                        This is to advise you
that we do not intend to review your registration statement.

               We request that you publicly file your registration statement no
later than 48 hours prior
       to the requested effective date and time. Please refer to Rules 460 and
461 regarding requests for
       acceleration. We remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
       absence of action by the staff.

                                                        Please contact Chris
Edwards at (202) 551-6761 with any questions.




                             Sincerely,


                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Divakar Gupta